-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of NMPA shows that Hubei Youersheng Pharmaceutical's 1.
1 class new drug Tianxingkechuanpai has entered the administrative approval stage
.
If successfully approved for marketing, Tianxing Kechuan Patch will become the first category 1 innovative Chinese patent medicine approved in the field of respiratory diseases this year
.
1 class new drug Tianxingkechuanpai has entered the administrative approval stage
.
If successfully approved for marketing, Tianxing Kechuan Patch will become the first category 1 innovative Chinese patent medicine approved in the field of respiratory diseases this year
.
Tianxing Kechuan Paste is a traditional Chinese medicine external treatment ointment developed by Hubei College of Traditional Chinese Medicine, which mainly plays the role of relieving cough and relieving asthma .
Cough and asthma is a respiratory disease .
Chronic inflammation of the airways will affect the ventilation of the patient's lungs.
In severe cases, the patient may have difficulty breathing .
Cough and asthma is a respiratory disease .
Chronic inflammation of the airways will affect the ventilation of the patient's lungs.
In severe cases, the patient may have difficulty breathing .
According to data from Minet.
com, in 2020, the sales of Chinese patent medicines for terminal respiratory diseases in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will be close to 30 billion yuan
.
com, in 2020, the sales of Chinese patent medicines for terminal respiratory diseases in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will be close to 30 billion yuan
.
Sales of Chinese patent medicines for respiratory diseases in public medical institutions in China (unit: 10,000 yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In terms of innovative research and development of traditional Chinese medicine, respiratory diseases are the treatment areas that domestic pharmaceutical companies pay more attention to
.
In the past 2021, the State Food and Drug Administration has approved a total of 12 new Chinese medicines for the market, of which 4 are new drugs in the field of respiratory diseases, including Yinqiao Qingre Tablets, Huashi Baidu Granules, Xuanfei Baidu Granules, Qingfei Granules, etc.
Detox Granules
.
.
In the past 2021, the State Food and Drug Administration has approved a total of 12 new Chinese medicines for the market, of which 4 are new drugs in the field of respiratory diseases, including Yinqiao Qingre Tablets, Huashi Baidu Granules, Xuanfei Baidu Granules, Qingfei Granules, etc.
Detox Granules
.
Chinese patent medicines for respiratory diseases approved by the State Food and Drug Administration in 2021
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Since 2022, only one innovative Chinese medicine drug has been approved for marketing in China, which is the icariin soft capsuleof Beijing Shennuoji Medicine
.
The registration status of Tianxing Kechuan Patch of Hubei Youersheng Pharmaceutical has been changed to "under approval".
If it is successfully approved, it will become the second innovative Chinese medicine drug this year
.
.
The registration status of Tianxing Kechuan Patch of Hubei Youersheng Pharmaceutical has been changed to "under approval".
If it is successfully approved, it will become the second innovative Chinese medicine drug this year
.
Data source: Minet database, company announcement
Recently, the official website of NMPA shows that Hubei Youersheng Pharmaceutical's 1.
1 class new drug Tianxingkechuanpai has entered the administrative approval stage
.
If successfully approved for marketing, Tianxing Kechuan Patch will become the first category 1 innovative Chinese patent medicine approved in the field of respiratory diseases this year
.
1 class new drug Tianxingkechuanpai has entered the administrative approval stage
.
If successfully approved for marketing, Tianxing Kechuan Patch will become the first category 1 innovative Chinese patent medicine approved in the field of respiratory diseases this year
.
Tianxing Kechuan Paste is a traditional Chinese medicine external treatment ointment developed by Hubei College of Traditional Chinese Medicine, which mainly plays the role of relieving cough and relieving asthma .
Cough and asthma is a respiratory disease .
Chronic inflammation of the airways will affect the ventilation of the patient's lungs.
In severe cases, the patient may have difficulty breathing .
Cough and asthma is a respiratory disease .
Chronic inflammation of the airways will affect the ventilation of the patient's lungs.
In severe cases, the patient may have difficulty breathing .
According to data from Minet.
com, in 2020, the sales of Chinese patent medicines for terminal respiratory diseases in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will be close to 30 billion yuan
.
com, in 2020, the sales of Chinese patent medicines for terminal respiratory diseases in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will be close to 30 billion yuan
.
Sales of Chinese patent medicines for respiratory diseases in public medical institutions in China (unit: 10,000 yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In terms of innovative research and development of traditional Chinese medicine, respiratory diseases are the treatment areas that domestic pharmaceutical companies pay more attention to
.
In the past 2021, the State Food and Drug Administration has approved a total of 12 new Chinese medicines for the market, of which 4 are new drugs in the field of respiratory diseases, including Yinqiao Qingre Tablets, Huashi Baidu Granules, Xuanfei Baidu Granules, Qingfei Granules, etc.
Detox Granules
.
.
In the past 2021, the State Food and Drug Administration has approved a total of 12 new Chinese medicines for the market, of which 4 are new drugs in the field of respiratory diseases, including Yinqiao Qingre Tablets, Huashi Baidu Granules, Xuanfei Baidu Granules, Qingfei Granules, etc.
Detox Granules
.
Chinese patent medicines for respiratory diseases approved by the State Food and Drug Administration in 2021
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Since 2022, only one innovative Chinese medicine drug has been approved for marketing in China, which is the icariin soft capsule of Beijing Shennuoji Medicine
.
The registration status of Tianxing Kechuan Patch of Hubei Youersheng Pharmaceutical has been changed to "under approval".
If it is successfully approved, it will become the second innovative Chinese medicine drug this year
.
.
The registration status of Tianxing Kechuan Patch of Hubei Youersheng Pharmaceutical has been changed to "under approval".
If it is successfully approved, it will become the second innovative Chinese medicine drug this year
.
Data source: Minet database, company announcement
Recently, the official website of NMPA shows that Hubei Youersheng Pharmaceutical's 1.
1 class new drug Tianxingkechuanpai has entered the administrative approval stage
.
If successfully approved for marketing, Tianxing Kechuan Patch will become the first category 1 innovative Chinese patent medicine approved in the field of respiratory diseases this year
.
1 class new drug Tianxingkechuanpai has entered the administrative approval stage
.
If successfully approved for marketing, Tianxing Kechuan Patch will become the first category 1 innovative Chinese patent medicine approved in the field of respiratory diseases this year
.
Tianxing Kechuan Paste is a traditional Chinese medicine external treatment ointment developed by Hubei College of Traditional Chinese Medicine, which mainly plays the role of relieving cough and relieving asthma .
Cough and asthma is a respiratory disease .
Chronic inflammation of the airways will affect the ventilation of the patient's lungs.
In severe cases, the patient may have difficulty breathing .
TCM TCM disease disease disease_Cough and asthma is a respiratory disease .
Chronic inflammation of the airways will affect the ventilation of the patient's lungs.
In severe cases, the patient may have difficulty breathing .
According to data from Minet.
com, in 2020, the sales of Chinese patent medicines for terminal respiratory diseases in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will be close to 30 billion yuan
.
hospital hospital hospitalcom, in 2020, the sales of Chinese patent medicines for terminal respiratory diseases in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will be close to 30 billion yuan
.
Sales of Chinese patent medicines for respiratory diseases in public medical institutions in China (unit: 10,000 yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In terms of innovative research and development of traditional Chinese medicine, respiratory diseases are the treatment areas that domestic pharmaceutical companies pay more attention to
.
In the past 2021, the State Food and Drug Administration has approved a total of 12 new Chinese medicines for the market, of which 4 are new drugs in the field of respiratory diseases, including Yinqiao Qingre Tablets, Huashi Baidu Granules, Xuanfei Baidu Granules, Qingfei Granules, etc.
Detox Granules
.
.
In the past 2021, the State Food and Drug Administration has approved a total of 12 new Chinese medicines for the market, of which 4 are new drugs in the field of respiratory diseases, including Yinqiao Qingre Tablets, Huashi Baidu Granules, Xuanfei Baidu Granules, Qingfei Granules, etc.
Detox Granules
.
Chinese patent medicines for respiratory diseases approved by the State Food and Drug Administration in 2021
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
Since 2022, only one innovative Chinese medicine drug has been approved for marketing in China, which is the icariin soft capsule of Beijing Shennuoji Medicine
.
The registration status of Tianxing Kechuan Patch of Hubei Youersheng Pharmaceutical has been changed to "under approval".
If it is successfully approved, it will become the second innovative Chinese medicine drug this year
.
medicine medicine medicine.
The registration status of Tianxing Kechuan Patch of Hubei Youersheng Pharmaceutical has been changed to "under approval".
If it is successfully approved, it will become the second innovative Chinese medicine drug this year
.
Data source: Minet database, company announcement
Data source: Minet database, company announcement 
